Abstract:
Objective: The study aims to determine whether ACEI/ARB use associated with an increased probability of viral infection and investigate whether there are differences in disease severity and mortality between ACEI/ARB users and non-ACEI/ARB users. Material and methods: In this retrospective study, 330 patients with severe acute respiratory syndrome coronavirus 2 disease were divided into two groups: patients using ACEI/ARB Blocker and patients not using it. Baseline features and prognoses were compared for the two groups. Results: The rate of intensive care hospitalization in the group using ACE/ARB was significantly (p<0.05) higher than the group not using ACEI/ARB on the day of hospitalization in the intensive care unit. The degree of clinical classification in the group using ACEI/ARB was significantly (p<0.05) higher than the group not using ACE/ARB. The mortality rate in the group using ACE/ARB was significantly (p<0.05) higher than the group not using ACEI/ARB. Conclusion: Although it has been determined that the use of antihypertensive ACEI/ARB in COVID 19 patients is associated with mortality and survival, it has been concluded that the continuation of ACEI/ARB use would be more appropriate for the continuation of antihypertensive treatment.